Welcome to our dedicated page for Intelligent Bio Solutions SEC filings (Ticker: INBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D milestones, biosensor patents, and drug-screening kit sales turn every Intelligent Bio Solutions Inc (INBS) filing into a technical maze. Stock Titan’s AI spots critical shifts—whether a new clinical study boosts revenue or an FDA update changes the regulatory timetable—so you no longer wade through hundreds of pages.
Track activity the moment it happens: Intelligent Bio Solutions insider trading Form 4 transactions and Intelligent Bio Solutions Form 4 insider transactions real-time appear on your dashboard seconds after EDGAR posts them. Need performance metrics? Open the Intelligent Bio Solutions quarterly earnings report 10-Q filing and read an AI snapshot that benchmarks fingerprint-sweat kit sales. Sudden news? The Intelligent Bio Solutions 8-K material events explained card tells you what changed and why.
Our platform offers comprehensive coverage of ALL filing types, each linked to a practical question:
- Is gross margin expanding? See the Intelligent Bio Solutions earnings report filing analysis inside the 10-Q.
- How is leadership paid? The Intelligent Bio Solutions proxy statement executive compensation section is distilled for quick review.
- Looking for long-term trends? The Intelligent Bio Solutions annual report 10-K simplified compiles five years of segment data.
Use these insights when understanding Intelligent Bio Solutions SEC documents with AI to monitor Intelligent Bio Solutions executive stock transactions Form 4 alerts, compare biosensor revenue over time, and prepare for upcoming catalysts. Real-time updates, AI-powered summaries, and expert context turn complex disclosures into clear answers.
Intelligent Bio Solutions Inc. (INBS) reported operating results and disclosures in its Form 10-K showing continued commercial rollout of its Intelligent Fingerprinting (IFP) products and persistent losses that raise near-term financing risk. The company installed over 1,000 IFP readers, added 115 new customer accounts, launched localized websites in Arabic, Italian and Spanish, was granted a U.S. patent for its drug screening cartridge, and completed a pharmacokinetic study supporting a 510(k) submission (Dec 2024) for codeine detection.
Financially, revenue line items include reader sales of $711,737 (FY2025) with GAAP gross profit of $1,246,859. The company recorded a net loss of $10,604,886, shareholders' equity of $2,813,824, a working capital deficit of $1,212,419, and an accumulated deficit of $62,533,065. Management discloses an explanatory audit paragraph on its ability to continue as a going concern and states it will need to raise additional capital within twelve months.
Intelligent Bio Solutions, Inc. (INBS) filed a Form D reporting a Regulation D, Rule 506(b) offering in which the issuer raised $3,839,356. The filing shows the total amount offered equaled the amount sold, with
FAQ
What is the current stock price of Intelligent Bio Solutions (INBS)?
What is the market cap of Intelligent Bio Solutions (INBS)?
